Follow Us On Facebook
500 W san Bernardino RD, STE A, Covina, CA 91722
Call :
626-966-1909 | Email :
Patient PortalPay NowVirtual Visit


1- Low Dose Naltrexone in the Treatment of Fibromyalgia

2- Trial of Anifrolumab in Active Systemic Lupus Erythematosus
3- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

4- Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis
5- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomized controlled trial
6- Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial
7- Autoinflammation and Immunomodulation in Inflammatory Fibromyalgia Syndrome- A Review
8- Improvement of Nerve Fiber Density in Fibromyalgia Patients Treated with IVIg.
9- Inflammatory Fibromyalgia: Is it Real?
10- Hip arthroplasty in a 101-year-old patient.
11- Rituximab treatment for resistant antiphospholipid syndrome.
12- Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab
13- Giant cell arteritis with visual loss following zoledronic acid infusion.
14- Pregnancy in a patient with gouty arthritis secondary to pseudo-Bartter syndrome
15- Inflammatory arthritis secondary to metastatic gastric cancer.

16- Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis
17- Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis
18- Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud’s disease

19- The use of the tumor necrosis factor antagonist infliximab in heart transplant recipients: two case reports
20- B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations

21-  Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus